South53 has secured seed funding to broaden its patent portfolio, complete product development, pilot manufacturing and prepare for first-in-human studies and regulatory submissions. The company plans to rapidly advance in stealth-mode to complete development of its first novel product for vascular access.
South53 announced that it hired experienced medical device executive and entrepreneur Rodney Brenneman as CEO. Mr. Brenneman has over 30 years of executive leadership, device development, clinical trial, regulatory and start-up experience.
